JP Morgan Day 2: Allergan and Alkermes rise on patents and pipelines
This article was originally published in Scrip
Specialty pharmaceutical companies took center stage on the second day of the 32nd Annual JP Morgan Healthcare Conference in San Francisco on 14 January as Allergan and Alkermes each reached new stock price highs based on the increasing strength of their portfolios.
You may also be interested in...
Lilly is planning for growth even beyond the loss of patent protection for Trulicity in 2027. In addition to internal R&D, Smiley said a third of new drugs will come from business development.
Ying Huang was named CEO as his predecessor came under investigation in China and as partner Janssen was getting closer to seeking US FDA approval for its lead CAR-T therapy.
Public Company Edition: 2020 started with two $200m-plus initial public offerings plus five health care-focused special purpose acquisition corporations IPOs. Also, a Pfizer initiative backs three public companies, Fate’s $432m offering led recent FOPOs and Biocon Biologics receives more investment.